|
Newest
VIDAS assay from bioMérieux provides reliability
monitoring of prostate cancer
December
13, 2001—bioMérieux, Inc., announces the
U.S. introduction of its latest VIDAS assay, VIDAS TPSA.
VIDAS
TPSA is an Equimolar TPSA test, calibrated against the
STANFORD standard. It offers excellent reproducibility
even at low values. The VIDAS TPSA assay provides an
accurate determination of total PSA and delivers high-quality
results for precise and reliable monitoring of prostate
cancer patients.
Click here to read the press release
bioMeriéux
Receives PMA Approval for HIV-1 Viral Load Assay to Aid
in Prognosis and Therapeutic Monitoring
November
19, 2001 — bioMérieux, Inc. has received
Premarket Approval (PMA) from the United States Food
and Drug Administration (FDA) for its NucliSens®
HIV-1 QT quantitative viral load assay. Using the firm's
proprietary Nucleic Acid Sequence-Based Amplification
(NASBA) technology, the test identifies the level of
HIV-1 viral RNA in plasma and can be used to monitor
the effects of anti-retroviral therapy by measuring
changes in HIV-1 RNA levels.
Click here to read the press release
bioMérieux’s
Latest Educational Tool Looks Small but Carries a Big
Message Regarding the Use of D-Dimer in the Evaluation
of Venous Thromboembolism
October
19, 2001— Continued educational opportunities abound
in the field of Thrombosis, and one company in particular,
bioMérieux, has taken an active role lately in
creating informative, easy-to-use and enlightening interactive
educational tools.
Click here to read the press release
bioMérieux,
Inc Acquires Diagnostics Division of Organon Teknika
July
12, 2001—For nearly 40 years, bioMérieux
has been a leader in biological diagnostics bringing
innovative and high-performance solutions to today's
healthcare marketplace. In an effort to better serve
you and expand our product offerings, bioMérieux
has been fortunate to acquire the diagnostics division
of Organon Teknika from Akzo Nobel.
Click here to read the press release
June
13-15: bioMérieux, Inc. Offers Unique Outcomes
Management Seminars
May
25, 2001—bioMérieux, Inc., in association
with the West Virginia Schools of Medicine and Pharmacy,
has developed a seminar designed to help hospitals improve
patient care while better managing costs. Contact
your local bioMérieux representative for details.
Click here to read the press release
FDA
Approves Antibiotics for Vitek® 2 S.
pneumoniae Susceptibility Testing
April
2, 2001—Keeping ahead of emerging resistant organisms
is an ongoing challenge for medical professionals everywhere.
It became a little easier recently when the FDA approved
bioMérieux's Streptococcus pneumoniae susceptibility
card for clinical use.
Click
here to read the press release
Dr. Peter Gilligan, Ph.D. Receives bioMérieux
Sonnenwirth Award for Leadership in Clinical Microbiology
April
2, 2001—This year's bioMérieux Sonnenwirth
Award for Leadership in Clinical Microbiology, proudly
sponsored by bioMérieux, Inc., since 1986, honors
Peter H. Gilligan, Ph.D.
Click
here to read the press release
|
